GIVAUDAN : Jefferies maintains 'underperform' rating
We are leaving our fourth-quarter organic growth guidance essentially unchanged at around 10.9% (+283 bp vs. 8.1%), while maintaining our price target of CHF 3,400," says the analyst firm.
Givaudan and the sector as a whole continue to generate impressive organic growth. Our preference remains Novonesis/DSM-Firmenich, with greater upside potential for fiscal 2025' adds Jefferies.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Go to the original article.
Contact us to request a correction